Design of Novel FLT-3 Inhibitors Based on Dual-Layer 3D-QSAR Model and Fragment-Based Compounds in Silico

FMS-like tyrosine kinase 3 (FLT-3) is strongly correlated with acute myeloid leukemia, but no FLT-3-inhibitor cocomplex structure is available to assist the design of therapeutic inhibitors. Hence, we propose a dual-layer 3D-QSAR model for FLT-3 that integrates the pharmacophore, CoMFA, and CoMSIA. We then coupled the model with the fragment-based design strategy to identify novel FLT-3 inhibitors. In the first layer, the previously established model, Hypo02, was evaluated in terms of its correlation coefficient (r), RMS, cost difference, and configuration cost, with values of 0.930, 1.24, 106.45, and 16.44, respectively. Moreover, Fischer's cross-validation test of data generated by Hypo02 yielded a 98% confidence level, and the validation of the testing set yielded a best r value of 0.87. The features of Hypo02 were separated into two parts and then used to screen the MiniMaybridge fragment compound database. Nine novel FLT-3 inhibitors were generated in this layer. In the second layer, Hypo02 was subjected to an alignment rule to generate CoMFA- and CoMSIA-based models, for which the partial least-squares validation method was utilized. The values of q(2), r(2), and predictive r(2) were 0.58, 0.98, and 0.76, respectively, derived from the CoMFA model with steric and electrostatic fields. The CoMSIA model with five different fields yielded values of 0.54, 0.97, and 0.76 for q(2), r(2), and predictive r(2), respectively. The CoMFA and CoMSIA models were used to constrain 3D structures of the nine novel FLT-3 inhibitors. This dual-layer 3D-QSAR model constitutes a valuable tool to easily and quickly screen and optimize novel potential FLT-3 inhibitors for the treatment of acute myeloid leukemia.

[1]  Y. Furukawa,et al.  The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations , 2008, Oncogene.

[2]  Shuyan Li,et al.  Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors , 2008, J. Comput. Aided Mol. Des..

[3]  Kunal Roy,et al.  Pharmacophore mapping of arylamino-substituted benzo[b]thiophenes as free radical scavengers , 2010, Journal of molecular modeling.

[4]  Tanaji T. Talele,et al.  Structure-based CoMFA and CoMSIA study of indolinone inhibitors of PDK1 , 2009, J. Comput. Aided Mol. Des..

[5]  Dmitri I Svergun,et al.  Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. , 2011, Blood.

[6]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[7]  Hanry Yu,et al.  In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. , 2008, Leukemia research.

[8]  P. Sprague.  Automated chemical hypothesis generation and database searching with Catalyst , 1995 .

[9]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[10]  Sivaprakasam Prasanna,et al.  Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking , 2009, J. Comput. Aided Mol. Des..

[11]  Kavitha Bharatham,et al.  Pharmacophore modeling for protein tyrosine phosphatase 1B inhibitors , 2007, Archives of pharmacal research.

[12]  M. Taha,et al.  Discovery of DPP IV Inhibitors by Pharmacophore Modeling and QSAR Analysis followed by in silico Screening , 2008, ChemMedChem.

[13]  Yan Tang,et al.  CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia , 2005, Clinical Cancer Research.

[14]  F. Lu,et al.  The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.

[15]  Doriano Fabbro,et al.  Prediction of Resistance to Small Molecule FLT3 Inhibitors , 2004, Cancer Research.

[16]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[17]  Pascal Furet,et al.  Aromatic interactions with phenylalanine 691 and cysteine 828: a concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents. , 2006, Journal of medicinal chemistry.

[18]  S. Sivan,et al.  Molecular docking and 3D-QSAR studies on triazolinone and pyridazinone, non-nucleoside inhibitor of HIV-1 reverse transcriptase , 2010, Journal of molecular modeling.

[19]  K. Sakamoto,et al.  FMS‐Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia , 2006, Stem cells.

[20]  Hiroshi Maeda,et al.  KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. , 2009, Blood.

[21]  M. Sumakanth,et al.  Virtual Screening of Cathepsin K Inhibitors Using Docking and Pharmacophore Models , 2008, Chemical biology & drug design.

[22]  K. Mills,et al.  The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. , 2006, Blood.

[23]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[24]  Yun Tang,et al.  3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA , 2007, Journal of molecular modeling.

[25]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[26]  Raghuvir R. S. Pissurlenkar,et al.  3D-QSAR studies of Dipeptidyl peptidase IV inhibitors using a docking based alignment , 2007, Journal of molecular modeling.

[27]  P. Zarrinkar,et al.  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.

[28]  Madhu Chopra,et al.  Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using Catalyst , 2008, Journal of molecular modeling.

[29]  Yan-Ke Jiang,et al.  Molecular docking and 3D-QSAR studies on β-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors , 2010, Journal of molecular modeling.

[30]  Kiran Boppana,et al.  Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models. , 2009, European journal of medicinal chemistry.

[31]  T. Naoe,et al.  A Novel FLT3 Inhibitor FI-700 Selectively Suppresses the Growth of Leukemia Cells with FLT3 Mutations , 2007, Clinical Cancer Research.

[32]  Supa Hannongbua,et al.  Interactions between cycloguanil derivatives and wild type and resistance-associated mutant Plasmodium falciparum dihydrofolate reductases , 2009, J. Comput. Aided Mol. Des..

[33]  R. Lock,et al.  FLT-3: a new focus in the understanding of acute leukemia. , 2005, The international journal of biochemistry & cell biology.